Abstract
: The steadily increasing list of drugs associated with prolongation of the QT interval and torsades de pointes (TdP) constitute a medical problem of major concern. Hence, there is a need at an early stage to identify drug candidates with an inherent capacity to induce repolarization‐related proarrhythmias, avoiding exposure of large populations to potentially harmful drugs. Furthermore, the availability of clinically relevant and predictive animal models should reduce the risk that effective and potentially life‐saving drugs never reach the market. This review will discuss the pros and cons of somein vivoandin vitroanimal models for assessing proarrhythmia liability.

This publication has 41 references indexed in Scilit: